Terms ending in 2044
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,770,713 | Generative Protein Design with Composable Energy-Based Models In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 12,338,460 | Method for Generating T Cell Lineage Populations from Stem/Progenitor Cells In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 12,749,555 | Multipole Moment Based Coarse Grained Representation of Antibody Electrostatics In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 12,398,953 | Rapid Depressurization Controlled Ice Nucleation in Pharmaceutical Freeze-Drying In force · High confidence | Purdue Research Foundation | In force | High confidence | |
| US 12,516,118 | Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibodies and ANTI-CD79B Antibody Drug Conjugates In force · High confidence | Genentech, Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Genentech, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.